Health Minister Jason Copping. (Government of Alberta)

By rdnewsNOW Staff

Trikafta: Ages six to 11

Alberta provides children access to new cystic fibrosis drug

Jul 11, 2022 | 3:00 PM

The new cystic fibrosis drug Trikafta is now available as treatment for children in Alberta aged six to 11.

The use of Trikafta to treat children aged six to 11 was approved by Health Canada on April 19 and recommended for listing by the Canadian Agency for Drugs and Technologies in Health on July 6.

“Alberta was among the first provinces and territories to provide older children and adults with access to Trikafta. Once again, Alberta’s government is leading the way by quickly making this transformative medication available to younger children, giving them the same opportunity to realize an improved quality of life,” said Jason Copping, Minister of Health.

Previously, the drug was made available to eligible Albertans 12 years of age and older in September 2021. The medication is now approved for use by younger children and covered in Alberta.

“The Canadian CF Treatment Society thanks the Government of Alberta for acting fast to make Trikafta available for children six years and older. This announcement will completely change the course of life for many children living with cystic fibrosis. We thank Alberta for being one of the first provinces to make Trikafta available to adult CF patients last September and children today,” said Chris MacLeod, national chair for Canadian Cystic Fibrosis Treatment Society.

WHAT'S ON

Here is what's on this weekend in Medicine Hat and area: Dec. 13-15

2h ago

IN THE COMMUNITY

Medicine Hat's Mustard Seed adding new shelter spaces at Alberta government's request

Dec 12, 2024

HOLIDAYS

Medicine Hat Kiwanis hosting Christmas dinner, applications due Friday

Dec 12, 2024

Cystic fibrosis is a genetic disease in which mucus accumulates in the lungs, digestive tract and other parts of the body. Symptoms of cystic fibrosis may include a persistent cough, shortness of breath, frequent chest infections and weight loss.

“As an adult with severe cystic fibrosis disease progression, I have experienced the life-changing results Trikafta can bring and I am so thankful that children with this devastating, progressive disease may not have to suffer the same burden that we as adults have. They now have a chance for a much healthier and longer life because of your actions. As a parent I can feel their relief, as all you want for your children is for them to be able to reach their full potential. The access you provided today makes that a reality for the first time for parents of CF kids,” said Amanda Bartels, cystic fibrosis patient and lead CF Canada volunteer advocate for Alberta.

The government also provides coverage for cystic fibrosis drugs Kalydeco and Orkambi for those meeting eligibility criteria.